Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects

Psychopharmacology

Volumn 229, Issue 2, 2013, Pages 245-252

  Wong, Dean F ^a   Kuwabara, Hiroto ^a   Brašić, James Robert ^a   Stock, Thomas ^b   Maini, Atul ^a   Gean, Emily G ^a   Loebel, Antony ^c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b HARBOR HOSPITAL   (United States)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antipsychotic agents; Dopamine D2 receptors; Dose response relationship; Drug; Lurasidone; Positron emission tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; LURASIDONE; RACLOPRIDE C 11;

ABNORMAL ECG; ABNORMAL LABORATORY RESULT; ABNORMAL VITAL SIGN; ADULT; AFRICAN AMERICAN; AKATHISIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BODY MASS; CAUDATE NUCLEUS; COHORT ANALYSIS; CORPUS STRIATUM; DIZZINESS; DOPAMINE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; GALACTORRHEA; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RADIATION DEPTH DOSE; SIDE EFFECT; SINGLE DRUG DOSE; URINARY FREQUENCY;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BRAIN; BRAIN MAPPING; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; HEALTHY VOLUNTEERS; HUMANS; ISOINDOLES; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; THIAZOLES; YOUNG ADULT;

EID: 84883456045     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3103-z     Document Type: Article

References (34)

1. Abanades S, van der Aart J, Barletta JA, Marzano C, Searle GE, Salinas CA, Ahmad JJ, Reiley RR, Pampols-Maso S, Zamuner S, Cunningham VJ, Rabiner EA, Laruelle MA, Gunn RN (2011) Prediction of repeat-dose occupancy from single-dose data: characterization of the relationship between plasma pharmacokinetics and brain target occupancy. J Cereb Blood Flow Metab 31:944-952
2. Ashburner, J, Friston, KJ (2003) Rigid body registration. In Frackowiak, RSJ, Friston, KJ, Frith, C, Dolan, R (eds) Human brain function, 2nd edition. Academic Press, pp 635-654
3. Baumann B, Danos P, Krell D, Diekmann S, Leschinger A, Stauch R, Wurthmann C, Bernstein HG, Bogerts B (1999) Reduced volume of limbic system-affiliated basal ganglia in mood disorders: preliminary data from a postmortem study. J Neuropsychiatry Clin Neurosci 11:71-78
4. Citrome L (2011) Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 65:189-210
5. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE (1994) Performance characteristics of a whole-body PET scanner. J Nuc Med 35:1398-1406
6. Ehret MJ, Sopko M, Lemieux T (2010) Focus on lurasidone: a new atypical antipsychotic for the treatment of schizophrenia. Formulary 45:313-317
7. Ehrin E, Farde L, Paulis T, Eriksson L, Greitz T, Johnström P, Litton JE, Nilsson JL, Sedval G, Stone-Elander S (1985) Preparation of 11C-labelled Raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey. Int J Appl Radiat Isot 36:269-273
8. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B (1995) Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15(Suppl 1):19S-23S
9. Gründer G, Landvogt C, Vernaleken I, Buchholz HG, Ondracek J, Siessmeier T, Härtter S, Schreckenberger M, Stoeter P, Hiemke C, Rösch F, Wong DF, Bartenstein P (2006) The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacol 31:1027-1035
10. Ichise M, Toyama H, Innis RB, Carson RE (2002) Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 22:1271-1281
11. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539
12. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334:171-181
13. Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293
14. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520
15. 11C]raclopride PET study. Psychopharmacology (Berl) 217:515-523
16. Latuda Prescribing Information (2012) Accessed on the web on May 31, 2012 at: http://www.latuda.com/LatudaPrescribingInformation.pdf
17. Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali Ah, Pikalov A, Potkin SG (2013a) Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizoprenia: a ramdomized, double-blind, placedo- and active-controlled trial. Schizophr Res 145:101-109
18. Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM (2013b) Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study. Schizophr Res. doi: 10.1016/j.schres.2013.03.013
19. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P (1997) Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 16:187-198
20. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G (2004) A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161:818-825
21. Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, Kapur S (2008) Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 69:81-86
22. Meltzer HY, Cucchiaro J, Silva RS, Ogasa M, Philips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A (2011) Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 168:957-967
23. Meyer JM, Loebel AD, Schweizer E (2009) Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 18:1715-1726
24. Moons T, de Roo M, Claes S, Dom G (2011) Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12:1193-1211
25. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A (2009) Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 70:829-836
26. Oswald LM, Wong DF, McCaul M, Zhou Y, Kuwabara H, Choi L, Brasic J, Wand GS (2005) Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacol 30:821-832
27. Sakurai, H, Bies, RR, Stroup, ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H, 2012. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull [Epub ahead of print]
28. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423
29. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC (2011a) Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol 31:497-502
30. 2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol 31:318-325
31. 3- receptor occupancy of ziprasidone). J Clin Psychopharmacol 28:608-617
32. Westlind A, Löfberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201-215
33. Wong DF, Tauscher J, Gründer G (2009) The role of imaging in proof of concept CNS drug discovery and development. Neuropsychopharmacol 34:187-203
34. 11C]raclopride. Neuropsychopharmacol 27:248-259